



www.genfit.com

GENFIT: NEW CONVERSIONS INTO SHARES OF 25 BONDS OCA2012-2

Lille (France), Boston (Massachusetts, United States), January 15th, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the conversions into shares of 25 bonds OCA2012-2 in keeping with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd.

In keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders' Meeting held on December 18th, 2012 and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), the Bondholder requested two new conversions on January 10th and January 11th, 2013 for a total value of €250,000.

The first conversion of 15 bonds OCA2012-2 into 47,701 new shares was performed at a conversion rate of €3.14, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (January 3rd - January 9th, 2013) prior to the conversion request.

This second conversion of 10 bonds OCA2012-2 into 31,481 new shares was performed at a conversion rate of €3.18, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (January 4th - January 10th, 2013) prior to the conversion request.

As a result of these two reserved share issues:

- The social capital of GENFIT has increased from €4,031,538.25 to €4,051,333.75;
- The number of shares representing the social capital of GENFIT has increased by 79,182, from 16,126,153 to 16,205,335 shares;
- The amount of the first installment of the bond loan agreement that remains to be converted is €350,000.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr